Effects of raloxifene treatment on the phenotype of blood monocytes
| Autor: | Dany Brohée, Jean Ducobu, Philippe Cauchie, Patrick Durez, Michel Vanhaeverbeek, Claude Remacle, Didier OberweisD. Oberweis, Catherine GregoirC. Gregoir, M. Guillaume, Karim Zouaoui Boudjeltia |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Selective Estrogen Receptor Modulators
medicine.medical_specialty Physiology medicine.medical_treatment Lipopolysaccharide Receptors Coronary Disease Fibrinogen Monocytes Leukocyte Count chemistry.chemical_compound Physiology (medical) White blood cell Internal medicine Fibrinolysis medicine Humans Raloxifene L-Selectin Aged Pharmacology biology Cholesterol Monocyte Cholesterol HDL General Medicine Lipoprotein(a) Middle Aged Flow Cytometry Postmenopause Endocrinology medicine.anatomical_structure chemistry Selective estrogen receptor modulator Raloxifene Hydrochloride biology.protein Cytokines Female medicine.drug |
| Zdroj: | Canadian Journal of Physiology and Pharmacology. 88:601-605 |
| ISSN: | 1205-7541 0008-4212 |
| Popis: | Raloxifene (RLX), a selective oestrogen receptor modulator, has oestrogen-agonist effects on bone, lipoproteins, and homocysteine and oestrogen-antagonist activity in the breast and uterus, positioning it as a potential drug for long-term prevention of coronary heart disease in postmenopausal women. To further evaluate its influence on cardiovascular risk factors, we studied the effects of 60 mg/day RLX on serum lipid levels, inflammatory (high-sensitivity C-reactive protein, and coagulation (fibrinogen) markers, monocytes, and fibrinolysis in 15 healthy postmenopausal women. Markers were measured at baseline, after 1 month without treatment, and after 3 months of treatment. Fibrinolysis was evaluated using the euglobulin clot lysis time (ECLT) determined with a new semiautomatic optical method. Monocyte phenotype was determined by measurement of the expression of the antigens CD14, HLA-DR, and CD62-L using flow cytometry. After 3 months of RLX treatment, we observed a decrease in total cholesterol (p = 0.002), in low-density lipoprotein cholesterol (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|